ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Sam_123
|
226 |
76K |
1 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
76K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Sam_123
|
226 |
76K |
5 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
76K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
Sam_123
|
78 |
23K |
2 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
78
|
23K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
Sam_123
|
78 |
23K |
12 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
78
|
23K
|
12
|
|
ASX - By Stock
|
OZM |
Re:
Ann: Top 20 Holders
|
|
Sam_123
|
18 |
5.4K |
0 |
08/02/21 |
08/02/21 |
ASX - By Stock
|
18
|
5.4K
|
0
|
|
ASX - By Stock
|
OZM |
Re:
Ann: Top 20 Holders
|
|
Sam_123
|
18 |
5.4K |
0 |
08/02/21 |
08/02/21 |
ASX - By Stock
|
18
|
5.4K
|
0
|
|
ASX - By Stock
|
OZM |
Re:
Ann: Top 20 Holders
|
|
Sam_123
|
18 |
5.4K |
0 |
08/02/21 |
08/02/21 |
ASX - By Stock
|
18
|
5.4K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Sam_123
|
1.0K |
515K |
0 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
1.0K
|
515K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Sam_123
|
1.0K |
515K |
20 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
1.0K
|
515K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Sam_123
|
1.0K |
515K |
1 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
515K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Sam_123
|
1.0K |
515K |
10 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
515K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Sam_123
|
1.0K |
515K |
1 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
515K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
4.9M |
0 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Sam_123
|
796 |
393K |
1 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
796
|
393K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
4.9M |
10 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
10
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
4.9M |
5 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
4.9M |
26 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
26
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
Sam_123
|
1.0K |
416K |
6 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
1.0K
|
416K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Guess the reason for MSB Trading Halt
|
|
Sam_123
|
317 |
155K |
3 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
317
|
155K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
4.9M |
2 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Sam_123
|
796 |
393K |
3 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
796
|
393K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Sam_123
|
796 |
393K |
44 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
393K
|
44
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Sam_123
|
192 |
86K |
2 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
192
|
86K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Did Mesoblast ever received any kind of FDA approval?
|
|
Sam_123
|
14 |
5.5K |
8 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
14
|
5.5K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
Sam_123
|
1.0K |
416K |
7 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
1.0K
|
416K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
4.9M |
5 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Phase 3 DREAM HF-1 read-out
|
|
Sam_123
|
344 |
178K |
15 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
344
|
178K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
4.9M |
1 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
4.9M |
4 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
4.9M |
3 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
Sam_123
|
572 |
250K |
10 |
08/12/20 |
08/12/20 |
ASX - By Stock
|
572
|
250K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
4.9M |
1 |
08/12/20 |
08/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
|
|
Sam_123
|
139 |
72K |
35 |
08/12/20 |
08/12/20 |
ASX - By Stock
|
139
|
72K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
|
|
Sam_123
|
139 |
72K |
14 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
139
|
72K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
|
|
Sam_123
|
139 |
72K |
36 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
139
|
72K
|
36
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
Sam_123
|
572 |
250K |
13 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
572
|
250K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
|
|
Sam_123
|
139 |
72K |
49 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
139
|
72K
|
49
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
|
|
Sam_123
|
139 |
72K |
109 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
139
|
72K
|
109
|
|
ASX - By Stock
|
MSB |
Re:
Guess the opening price - if ARDS halted due supreme efficacy
|
|
Sam_123
|
416 |
130K |
4 |
03/12/20 |
03/12/20 |
ASX - By Stock
|
416
|
130K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Guess the opening price - if ARDS halted due supreme efficacy
|
|
Sam_123
|
416 |
130K |
1 |
03/12/20 |
03/12/20 |
ASX - By Stock
|
416
|
130K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
4.9M |
0 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
Sam_123
|
572 |
250K |
25 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
250K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
Sam_123
|
811 |
332K |
23 |
30/11/20 |
30/11/20 |
ASX - By Stock
|
811
|
332K
|
23
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Sam_123
|
17K |
6.6M |
7 |
30/11/20 |
30/11/20 |
ASX - By Stock
|
17K
|
6.6M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Sam_123
|
17K |
6.6M |
5 |
30/11/20 |
30/11/20 |
ASX - By Stock
|
17K
|
6.6M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Sam_123
|
17K |
6.6M |
17 |
30/11/20 |
30/11/20 |
ASX - By Stock
|
17K
|
6.6M
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Ann: CEO Presentation to 2020 Annual General Meeting
|
|
Sam_123
|
13 |
7.4K |
35 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
13
|
7.4K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Sam_123
|
17K |
6.6M |
12 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
17K
|
6.6M
|
12
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
4.9M |
12 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
13K
|
4.9M
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
Sam_123
|
811 |
332K |
53 |
22/11/20 |
22/11/20 |
ASX - By Stock
|
811
|
332K
|
53
|
|